Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies

G Cozzi, L Scagnellato, M Lorenzin… - Nature Reviews …, 2023 - nature.com
Spondyloarthritis (SpA) encompasses a heterogeneous group of chronic inflammatory
diseases that can affect both axial and peripheral joints, tendons and entheses. Among the …

[HTML][HTML] The Role of Genetic and Epigenetic Regulation in Intestinal Fibrosis in Inflammatory Bowel Disease: A Descending Process or a Programmed Consequence?

S Jarmakiewicz-Czaja, A Sokal, K Ferenc, E Motyka… - Genes, 2023 - mdpi.com
Inflammatory bowel diseases (IBDs) are a group of chronic diseases characterized by
recurring periods of exacerbation and remission. Fibrosis of the intestine is one of the most …

[HTML][HTML] Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation

M Salla, J Guo, H Joshi, M Gordon, H Dooky… - International Journal of …, 2023 - mdpi.com
Persistent inflammation can trigger altered epigenetic, inflammatory, and bioenergetic
states. Inflammatory bowel disease (IBD) is an idiopathic disease characterized by chronic …

[HTML][HTML] The earlier you find, the better you treat: red flags for early diagnosis of inflammatory bowel disease

L Cantoro, R Monterubbianesi, G Falasco, C Camastra… - Diagnostics, 2023 - mdpi.com
Delayed diagnosis is a challenge in the management of inflammatory bowel disease (IBD).
Several studies show a significant association between diagnostic delay and disease …

[HTML][HTML] Role of Serum Interleukin-6, Interleukin-1β and Interleukin-10 in Assessment of Disease Activity and Nutritional Status in Patients with Inflammatory Bowel …

M Godala, E Gaszyńska, K Walczak… - Journal of Clinical …, 2023 - mdpi.com
Inflammatory bowel diseases (IBD) are characterised by multifactorial and chronic
inflammation. Much attention has been paid to immune dysfunction in inflammatory bowel …

[HTML][HTML] Rosiglitazone does not affect the risk of inflammatory bowel disease: a retrospective cohort study in Taiwanese type 2 diabetes patients

CH Tseng - Pharmaceuticals, 2023 - mdpi.com
Human studies on the effect of rosiglitazone on inflammatory bowel disease (IBD) are still
lacking. We investigated whether rosiglitazone might affect IBD risk by using the …

An inflammation-related subtype classification for analyzing tumor microenvironment and clinical prognosis in colorectal cancer

J Pei, Y Gao, A Wu - Frontiers in Immunology, 2024 - frontiersin.org
Background The inflammatory response plays an essential role in the tumor
microenvironment (TME) of colorectal cancer (CRC) by modulating tumor growth …

Inflammatory bowel disease alters in vivo distribution of orally administrated nanoparticles: Revealing via SERS tag labeling technique

M Tan, Y Wang, Y Ji, R Mei, X Zhao, J Song, J You… - Talanta, 2024 - Elsevier
Nanoparticles (NPs) could be uptake orally and exposed to digestive tract through various
sources such as particulate pollutant, nanomedicine and food additive. Inflammatory bowel …

[HTML][HTML] 90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients

PL Pesole, M Liso, R Donghia, V Guerra… - International Journal of …, 2023 - mdpi.com
Inflammatory bowel diseases (IBD), comprising Crohn's disease (CD) and Ulcerative Colitis
(UC), are multifactorial disorders characterized by a chronic inflammatory status with the …

[HTML][HTML] Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease

P Puca, I Capobianco, G Coppola… - International Journal of …, 2024 - mdpi.com
The advent of biologic drugs has revolutionized the treatment of Inflammatory Bowel
Disease, increasing rates of response and mucosal healing in comparison to conventional …